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Systematic reviews in paediatric multiple
sclerosis and Creutzfeldt-Jakob disease
exemplify shortcomings in methods used
to evaluate therapies in rare conditions
Steffen Unkel1*, Christian Röver1, Nigel Stallard2, Norbert Benda3, Martin Posch4, Sarah Zohar5 and Tim Friede1
Abstract
Background: Randomized controlled trials (RCTs) are the gold standard design of clinical research to assess
interventions. However, RCTs cannot always be applied for practical or ethical reasons. To investigate the current
practices in rare diseases, we review evaluations of therapeutic interventions in paediatric multiple sclerosis (MS)
and Creutzfeldt-Jakob disease (CJD). In particular, we shed light on the endpoints used, the study designs
implemented and the statistical methodologies applied.
Methods: We conducted literature searches to identify relevant primary studies. Data on study design, objectives,
endpoints, patient characteristics, randomization and masking, type of intervention, control, withdrawals and
statistical methodology were extracted from the selected studies. The risk of bias and the quality of the studies
were assessed.
Results: Twelve (seven) primary studies on paediatric MS (CJD) were included in the qualitative synthesis. No
double-blind, randomized placebo-controlled trial for evaluating interventions in paediatric MS has been published
yet. Evidence from one open-label RCT is available. The observational studies are before-after studies or controlled
studies. Three of the seven selected studies on CJD are RCTs, of which two received the maximum mark on the
Oxford Quality Scale. Four trials are controlled observational studies.
Conclusions: Evidence from double-blind RCTs on the efficacy of treatments appears to be variable between rare
diseases. With regard to paediatric conditions it remains to be seen what impact regulators will have through
e.g., paediatric investigation plans. Overall, there is space for improvement by using innovative trial designs and
data analysis techniques.
Keywords: Clinical trials, Creutzfeldt-Jakob disease, Evidence synthesis, Paediatric multiple sclerosis, Rare diseases,
Systematic review
Background
Rare diseases, also referred to as orphan diseases, are
illnesses that affect a predefined small proportion of the
population. No single cut-off number has been globally
agreed upon for which a disease is considered rare and,
not surprisingly, various definitions for rare diseases do
exist. For example, the European Commission defines
the prevalence for a rare disease as affecting no more
than 5 per 10 000 persons in the European Union (EU)
[1]. It is estimated that at present in the EU, 5000–8000
distinct rare diseases affect 6–8 % of the population,
that is, between 27 and 36 million people [2]. Hence,
rare diseases create an enormous health and economic
burden and research on these deserves considerable
attention.
Most rare diseases have a genetic basis and onset is
often in childhood and adolescence [2]. Many rare
conditions have neurological manifestations [3], of which
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two prominent examples are paediatric multiple sclerosis
(MS) and Creutzfeldt-Jakob disease (CJD). Multiple
sclerosis is a disease characterized by recurrent immune-
mediated episodes of central nervous system demyelin-
ation [4]. Signs and symptoms such as losing the ability to
walk independently vary widely, depending on the amount
of damage and which areas of the brain are affected. To
date there is no cure for MS. However, medications can
help speed recovery from attacks of worsening neurologic
function, prevent attacks, modify the course of the disease
and manage symptoms. Multiple sclerosis has an esti-
mated prevalence of more than 1 individual in 1000
persons and is therefore not rare [5]. Its onset is usually
in adult life but in 3–5 % of cases MS manifests before
the age of 18 years [6]. Therefore, multiple sclerosis in
the subgroup of children and adolescents is rare. The
relapse-remitting course is the overwhelming manifest-
ation in early-onset MS with most symptoms of MS
similar to those seen in adults [7].
Creutzfeldt-Jakob disease is a fatal, untreatable prion
encephalopathy. The estimated prevalence of CJD is 1–9
cases per 1,000,000 people [8]. Most frequently, CJD is
marked by rapid mental deterioration. The disease
evolves into a state of akinetic mutism and ususally leads
to death within a few months. Treatment is aimed at
alleviating symptoms and making the patient as com-
fortable as possible [9].
Some major obstacles for expanding knowledge of rare
diseases such as paediatric MS and CJD do exist [10, 11].
Firstly, given the small sample size there is lack of clarity
on how to design and conduct proper clinical trials to in-
vestigate the effects of therapeutic interventions. Whereas
in large populations usually two independent randomised
controlled trials (RCTs) are required to demonstrate
efficacy and safety for marketing authorization, in
small populations the conduct of even a single large-
scale confirmatory trial might be extremely difficult
or not feasible. Besides, if a disease is rare in the subgroup
of children or adolescent patients, then one is faced with
general ethical and practical challenges of designing and
conducting paediatric studies. Secondly, the generation of
evidence for rare conditions is often hindered by the lack
of knowledge about the clinical course of the disease.
Thirdly, the small patient populations can dampen com-
merical interest in the development of drugs or therapies.
Nevertheless, the past decade has witnessed an increase
in research activity on the methodological and statistical
issues that are related to the evaluation of interventions in
rare diseases and small patient populations. The growth in
this area has been so rapid as to spawn conferences, new
journals, e.g., the Rare Diseases and Orphan Drugs Journal
and the Orphanet Journal of Rare Diseases, and a scien-
tific guideline on clinical trials in small populations pub-
lished by the European Medicines Agency (EMA) in 2006
[12]. In this regulatory guideline, a range of approaches
are discussed that may be helpful at the design stage of
small clinical trials such as response-adaptive designs and
n-of-1 trials. Randomized response-adaptive designs are
schemes for patient assignment to treatment, the goal of
which is to place more patients on the better treatment
based on patient responses already accrued in the trial
[13]. A randomized n-of-1 study is a clinical trial in which
random allocation is used to determine the order in which
an experimental and a control intervention are given to a
single patient [14].
At the stage of data analysis, sensitivity analyses con-
sisting of various statistical models that make different
assumptions about the data should be carried out. The
EMA Guideline on clinical trials in small populations
also states that the use of Bayesian methods [15] could
be advantageous when faced with small datasets because
these methods offer a way to combine knowledge from
previous data or prior knowledge with data from a study,
although introducing prior beliefs is often a concern in
drug regulation. As with sensitivity analyses, a variety of
reasonable prior distributions should be combined with
data from studies to ensure that conclusions are not too
much based on a specific prior distribution [12]. The
U.S. Food and Drug Administration (FDA) published a
draft guidance on rare diseases in August 2015 [16].
Some recently published reviews discuss clinical trial de-
signs and statistical methods that have been proposed or
described in the context of rare diseases and small popula-
tions [17–19]. More specifically, in [17], clinical trial de-
signs that have been proposed or employed in patients
with rare diseases are categorized into two groups: designst
that have the potential to reduce the expected trial sample
size such as adaptive designs and designs that increase the
number or fraction of on-treatment participants such as
randomized crossover trials in which subjects receive a se-
quence of different treatments. Methods for observational
data are categorized into four groups: methods to deal with
confounding, self-controlled study designs in which pa-
tients act as their own controls, case–control designs that
involve sampling from an underyling cohort of patients
and prospective inception cohorts that are cohorts that are
observed starting from a clearly defined point in time such
as time of beginning of treatment.
In contrast to [17–19], the purpose of the present paper
is to review the methods actually used in the evaluations
of therapeutic interventions by considering two prominent
rare diseases as examples, namely paediatric MS and CJD.
Instead of summarizing the evidence in a narrative
fashion, we provide a systematic review that is the result
of applying an explicit, rigorous and reproducible logic for
identifying and reporting relevant studies.
Although paediatric MS and CJD are clinically very
dissimilar, the methodological challenges in evaluating
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therapeutic interventions in these conditions bear some
similarities. Our focus has been on obtaining a qualita-
tive synthesis of the evidence from a methodological
perspective. In particular, in view of the paucity of a
large number of patients that are available for conduct-
ing clinical trials for paediatric MS and CJD, we aim to
shed light on the implemented study designs for investi-
gating the endpoints of interest and the statistical meth-
odologies applied to analyse the patient collectives. Our
review may offer a way for progressing the study of rare
diseases in general.
The remainder of this paper is organized as follows. In
Section 2, we describe the literature searches undertaken
to identify suitable primary studies for the two illnesses
of interest (Section 2.1) and the process of extracting
relevant data from those studies (Section 2.2). Section 3
summarizes the main findings; in Section 3.1 and Section
3.2 study selection and study characteristics, respectively,
are discussed and in Section 3.3 the methodological
quality of the studies is appraised. In Section 4, the
review's "take-home" messages are summarized and
the strengths and weaknesses of the evidence are dis-
cussed. In Section 5, a general interpretation of the
results in the context of other evidence is provided
and suggestions for future research are made.
Methods
The preferred reporting items for systematic reviews and
meta-analyses (PRISMA) statement [20] guided the writ-
ing up of the systematic reviews. The PRISMA checklist
of 27 essential items for transparent reporting is given in
Additional file 1: Table S1 in the supplementary web
material.
Systematic literature search and article selection
To choose appropriate literature search strategies
for the two illnesses under investigation, the PICOS
framework [21] was applied. More precisely, we
looked for
i. studies for the subgroup of children or adolescents
younger than 18 years of age with a diagnosis of MS
and patients with probable or definite CJD,
respectively;
ii. studies with any type of drug intervention;
iii. studies with either no control group or with a
control group existing of either placebo
concurrent controls, no treatment concurrent
controls, dose-comparison concurrent controls
(different doses or regimens of same treatment),
active treatment concurrent controls (different
active treatments), or historical (external and
non-concurrent) controls;
iv. studies with any type of outcome;
v. all evidence available from meta-analyses, RCTs and
controlled/uncontrolled prospective and retrospective
observational studies.
Observational studies are deemed to be relevant if at
least 20 people were contained in the treatment arm. This
imposed restriction eliminates individual case reports and
small case series and also may reduce publication
bias. Based on these PICOS specifications, publications
were identified from the electronic databases PubMed and
Cochrane Central Register of Controlled Trials (CEN-
TRAL), by using the following search strategies:
– Paediatric MS: (“Multiple Sclerosis/drug
therapy”[MeSH] AND (adolescents[Title/Abstract]
OR children[Title/Abstract] OR juvenile[Title/
Abstract] OR pediatric[Title/Abstract] OR
paediatric[Title/Abstract] OR “early onset”[Title/
Abstract])),
– CJD: (“Creutzfeldt-Jakob Syndrome/drug
therapy”[MeSH]).
All titles and abtracts were screened independently by
two reviewers (SU, CR). Full papers were reviewed if at
least one reviewer considered a paper relevant for the re-
view. Finally, the reference lists of all qualifying articles
were examined to supplement the search. The primary
studies selected were then submitted for data extraction.
Data extraction, risk of bias assessment tool and quality
scales
Using an electronic spreadsheet, the following data items
were extracted by one reviewer and verified by another:
 reference,
 aims/objectives of the study,
 study design,
 endpoints of interest,
 description of patient characteristics at the
beginning of study,
 method of randomization,
 method of blinding,
 type of intervention and intervention group,
 specification of the control group,
 withdrawals, dropouts, patients lost to follow-up, and
 statistical methodologies used to analyse the patient
collectives.
It is important to assess risk of bias in studies as dif-
ferences in risk of bias can help explain variation in the
results of studies included in a systematic review. The
Cochrane Collaboration’s recommended tool for asses-
sing risk of bias in RCTs is a domain-based evaluation,
in which critical assessments are made separately for
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different domains and then judgements are assigned to re-
late the risk of bias to each of the domains [22, 23]. This is
achieved by assigning a judgement of “low risk”, “high
risk” or “unclear risk” of bias to the domains covering se-
lection bias, performance bias, detection bias, attrition
bias and reporting bias. We have used the Cochrane
Collaboration’s tool for assessing the risk of bias of the
RCTs in patients with paediatric MS and CJD, respectively.
The quality of the selected primary studies has been
classified according to the scheme of the American
Academy of Neurology (AAN) for assigning levels of evi-
dence for therapeutic questions [24]. The AAN classifies
evidence using a four-tiered system (class I through class
IV), with class I indicating the strongest evidence and
class IV the weakest. The class of evidence is determined
both by the rigor of the study and the risk of bias. The cri-
teria used to determine the rigor of the study are similar
to those used by other entities that produce guidelines
and evidence statements. As with other classification
schemes, the presence or absence of randomization and a
control group are fundamental elements. A concise sum-
mary of the AAN classification scheme with the informa-
tion relevant for this review is given in Additional file 1:
Table S2 in the supplementary material.
In addition, RCTs have been assessed by means of the
Oxford Quality Scoring system [25]. The latter scale as-
sesses the quality of published clinical trials based on
methods relevant to random assignment, double blinding,
and the flow of patients (withdrawals and dropouts).
There are seven items. The last two attract a negative
score, which implies that the range of possible scores is 0
(very poor) to 5 (rigorous).
The methodological quality of studies included in
the review was assessed independently by two re-
searchers (SU, CR). Discrepancies in scoring were re-
solved through discussion.
Results
Study selection
Figures 1 and 2 represent the PRISMA four-phase flow
diagrams for the different phases of identification and
selection of primary studies on evaluating interventions
in paediatric MS and CJD, respectively. Using the search
strategies mentioned above, 130 abstracts (124 abstracts)
on paediatric MS (CJD) were retrieved from the PubMed
and CENTRAL databases. The database searches were
conducted on December 15th, 2015.
On the basis of an initial screening of the titles and ab-
stracts, 108 (114) records were excluded on paediatric
MS and CJD, respectively. It should be mentioned that
for paediatric MS, full-text versions of two records that
have been written in Russian and which may have been
eligible for inclusion in the review were not available
[26, 27]. Scanning the reference lists of the remaining
papers revealed a further two (six) papers that may have
been eligible for inclusion in the review. After reading
the entire manuscripts of twenty-one (thirteen) papers,
twelve (seven) primary studies on paediatric MS (CJD)
were included in the qualitative synthesis, and nine (six)
were excluded with reasons given in Figs. 1 and 2.
Study characteristics
Paediatric MS
Disease-modifying therapies for MS that were success-
fully tested for adults such as interferon-beta therapy,
natalizumab or glatiramer acetate are also tested in pa-
tients who are younger than 18 years. An overview about
the main characteristics of the twelve selected studies on
evaluations of therapeutic interventions in paediatric MS
is given in Additional file 1: Table S3. The typical end-
points under investigation are changes in the annualized
relapse rate (ARR) and in the expanded disability status
scale (EDSS) score. Studies also verify whether the of-
fered treatment is safe and well tolerated in children
and adolescent patients. No double-blind, randomized
placebo-controlled trial for evaluating interventions in
paediatric MS has been published yet. Evidence from
one RCT with a total sample size of sixteen patients is
available, but the RCT lacks appropriate blinding and the
patients in the control group receive no treatment ([28],
see also the editorial to the corresponding issue of Journal
of Neuropediatrics by A. Minagar).
The eleven observational studies are either uncon-
trolled treatment versus baseline trials in which patients
serve as their own controls or controlled trials including
natural history controls, dose-comparison concurrent
controls or active treatment concurrent controls. With
respect to the analysis of study populations, some stud-
ies seem to consider subgroups of patients of the same
registry [29–32]. The total sample sizes of the selected
studies varies from 16 to 307 (median 52). The RCT [28]
has the minimum size of all patient collectives. The
number of patients included in the observational studies
varies between 20, which is the lower bound imposed by
us, and 307.
Comparisons between pre- and post-treatment status
or between treatment groups were mostly done by
means of statistical hypothesis testing. Except for the
RCT [28], no study presented a justification of the sam-
ple size on the basis of a power analysis. A power ana-
lysis allows determining the sample size required to
reject the null hypothesis that there is no treatment ef-
fect when the alternative hypothesis is true. Conversely,
a power analysis also allows determining the probability
of rejecting the null hypothesis that there is no treat-
ment effect when the alternative hypothesis is true,
under sample size constraints [33]. The only study that
explicitly adjusted for multiple endpoints used the
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simple Bonferroni correction [26]. Some studies use
merely descriptive analyses, e.g., comparing frequencies,
to evaluate intervention effects.
The largest selected study on paediatric MS [34], the
study [35] and in part also the study [36] were industry
sponsored. With the exception of these three trials, the
remaining nine studies appear to be investigator initiated
trials. The randomized open-label trial [28] does not pro-
vide any information about sponsorship. Apart from the
RCT [28], the problem of confounding was addressed only
in the comparative observational trial [37], in which
regression techniques were applied to eliminate relevant
differences between the two treatment groups. Six out of
the eleven observational trials are prospective analyses.
CJD
No therapeutic intervention prevents or reverses the
progressive and ultimately fatal course of CJD. The
antibiotic doxycycline, the antiviral agent quinacrine and
the triaminopyridine compound flupirtine have been
tested in the selected studies. Therapies with these drugs
aim at alleviating pain and other symptoms and at mak-
ing people with CJD as comfortable as possible. An over-
view of the main characteristics of the seven selected
studies on evaluations of therapeutic interventions in
CJD are given in Additional file 1: Table S4. Not surprs-
ingly, all trials on patients who suffer from CJD investi-
gate time-to-event endpoints, such as survival time from
start of treatment to death, time to loss of autonomous
feeding, or time to reach the clinical stage of akinetic
mutism. In one trial, the primary endpoint was the dif-
ference in the cognitive part of the Alzheimer’s disease
assessment scale (ADAS-cog) [38]. Three of the seven
selected studies are double-blind RCTs. One RCTcontains
a randomized controlled portion and a non-randomized
portion [39]; the randomized portion of the trial ended at
Fig. 1 PRISMA four-phase flow diagram outlining identification and selection procedures for the studies on paediatric MS that are included in the
qualitative synthesis
Unkel et al. Orphanet Journal of Rare Diseases  (2016) 11:16 Page 5 of 11
month 2 and subjects returning for their month-2 visit
were offered open-label quinacrine. In one observational
study [40], patients were offered a choice between quina-
crine, no quinacrine, or randomisation to immediate
quinacrine or deferred quinacrine. Four trials are con-
trolled observational studies including natural history con-
trols or historical controls.
The three RCTs and the patient preference trial pre-
sented the sample size obtained from a power analysis
[38–41]. Some of the trials only investigate a single
primary endpoint. Apparently, in none of the trials that
investigate multiple endpoints was any adjustment for
multiple testing made. Standard Kaplan-Meier estimates
were used to measure the fraction of patients living for a
certain amount of time after treatment; they are non-
parametric as they do not require specific parametric as-
sumptions to be made about the underlying distribution
of survival times [42]. Kaplan-Meier curves for each
group of interest were then produced and plotted. The
formal comparisons of the survival curves of two groups
were based on a formal statistical test. Log-rank tests
were employed to test the null hypothesis that there is
no difference between the survivor functions of patients
in the two treatment groups and to establish the efficacy
of an experimental treatment in comparison with a con-
trol [42]. Cox proportional hazard models were applied
to analyse the effect of covariates on the survival experi-
ence of a patient. A Cox regression model provides an
estimate of the treatment effect on survival after adjust-
ment for other explanatory variables. In addition, it
allows estimating the cumulative risk of an event for an
individual, given her or his prognostic variables. The
proportional hazards condition requires the ratio of the
hazard functions in both treatment groups to remain
constant over time [42].
The total sample sizes of the selected studies vary from
28 to 157 (median 99). All studies investigated clinical
endpoints such as overall survival or time-to-disease
Fig. 2 PRISMA four-phase flow diagram outlining identification and selection procedures for the studies on CJD that are included in the
qualitative synthesis
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progression. Except for [38], which was partly commeri-
cally sponsored, six out of seven studies on CJD are ei-
ther non-commerically sponsored studies or, as in [43],
information about sponsoring was not reported. Two
out of the four observational studies are retrospective in
nature. The three RCTs address potential confounding
by randomization. The open-label patient preference
trial [40] adjusts for substantial differences between pa-
tients who chose to take quinacrine and those who did
not by means of stratification. Table 1 gives a summary
of the number of selected studies on paediatric MS and
CJD that meet certain methodological characteristics.
Risk of bias assessment and quality appraisal
Table 2 is a risk of bias summary which is part of the
Cochrane Collaboration’s tool for assessing risk of bias
in RCTs [22]. For each RCT, the judgement (low risk of
bias, high risk of bias or unclear risk of bias) is pre-
sented for the domains covering selection bias, perform-
ance bias, detection bias, attrition bias and reporting
bias. The RCTs [39, 41, 44] were judged to have a low
risk of bias across all domains indicating a high quality
in trial conduct and reporting. Recall that in the trial
[39] subjects who were originally randomized were of-
fered open-label treatment at month 2. Therefore, judge-
ments in Table 2 refer to the randomized portion of the
trial only. Since in trial [40] patients were offered a
choice between treatment, no treatment, or randomisa-
tion to immediate treatment or deferred treatment in an
open-label, patient-preference trial, this trial is consid-
ered an observational study. The single RCT on paediat-
ric MS has methodological flaws and shows a high-risk
of performance bias since neither participants nor
personnel are blinded to the allocation.
The results of the quality appraisal of the studies on
paediatric MS and CJD are presented in Table 3. The
evidence on paediatric MS is almost entirely based on
observational studies with the quality of studies being
classified as class III or class IV. Note that although
before-after designs are uncontrolled trials they are cate-
gorized in class III on the AAN scheme. In line with
[45] some before-after trials were classified as class IV
because they lack an independently derived outcome
measurement (T. Chitnis, personal communication, May
7th 2015). The single RCT [28] that is available for
paediatric MS is ranked class II on the AAN scheme be-
cause there is no evidence of concealed allocation; it
only received two points on the Oxford Quality Scale
because the method of randomisation is not described.
Moreover, the study is also not described as double-
blind.
For the case of CJD, three of the seven selected studies
are RCTs, of which two received the maximum mark on
the Oxford Quality Scale [39, 41]. The RCT [38] re-
ceived four points on this scale because although the
study is described as randomised, the method of ran-
domisation is not described. Since the seven selected
publications on CJD are either RCTs that fulfill the cri-
teria (a)-(d) stated in Additional file 1: Table S2 or are
controlled observational studies, they are classified as
class I or class III evidence on the AAN scale.
As indicated in Table 3, the quality of the available
evidence for CJD is far better than for paediatric MS.
However, the establishment of class I evidence on
the effects of therapeutic interventions in the paedi-
atric MS population is hindered by common practical
and ethical challenges of studies in children and ado-
lescents. We elaborate further on this point in the
Conclusions section.
Discussion
Summary of evidence and limitations
Both paediatric MS and CJD have been a focus of great
interest in recent years. For these two illnesses there is a
clear gap between the methods that have been proposed
for studying treatments in small samples and methods
that are currently in use. We have identified some short-
comings in the design, analysis and reporting of studies
in patients with paediatric MS or CJD. In particular for
paediatric MS, the statistical methodology used to ana-
lyse the patient collectives is fairly basic, sometimes
purely descriptive. One might argue that in studies with
few patients there is not much information and so sim-
ple analyses are all that are warranted. But regulatory au-
thorities emphasize that, especially for situations when
there are very few data, more complex approaches are
needed [12]. However, one should be aware that some of
the statistical methods that are mentioned in this paper
(e.g., hypothesis tests) are based on asymptotic or large
sample theory. Within the framework of large sample
theory it is typically assumed that the sample size is suf-
ficiently large, and the properties of statistical proce-
dures are evaluated in the limit as the sample size
approaches infinity. It may be questioned whether the
Table 1 Number of selected studies on paediatric MS and CJD meeting specific criteria
RCT Clinical
endpoints
Prospective
analysis
Sample size
calculation
Adjustments for
multiple testing
Confounding
addressed
Industry
sponsored
Paediatric MS (n = 12) 1 12 6 1 1 2 3
CJD (n = 7) 3 7 5 4 0 4 1
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asymptotic results can be treated as approximately valid
for small sample sizes as well.
Almost exclusively, the evidence on therapeutic inter-
ventions in paediatric MS found by our review is based
on observational studies with the quality of studies being
classified as class III or class IV. In most instances, how-
ever, observational data should not be relied upon solely
to determine whether treatments are efficacious; often
the greater biases of observational studies become apparent
when their findings are tested with appropriate scientific
methods in RCTs. Unfortunately, the single RCT available
on patients with paediatric MS suffers from several weak-
nesses including a very small sample size and lack of blind-
ing. Blinding to subcutaneous interferon-beta-1a treatment
could be obtained by allocating matching placebo intra-
muscular injections to the control group (see for example
ClinicalTrials.gov identifier: NCT00441103 for a completed
RCT in adult patients with MS).
One promising finding from the RCTs in patients with
CJD is that multicentre, occasionally multinational stud-
ies, fast enrolment and rigorous study methods with a
sufficient number of participants and low risk of bias
can be achieved for treatment of a rare, rapidly progres-
sive neurological disorder.
The present review has some limitations. Firstly, our
literature searches were focused on retrieving evidence on
two specific rare diseases. Because of the large number of
rare conditions that do exist, our review is not meant as a
comprehensive overview of methods that have been pro-
posed or applied across the spectrum of rare diseases and
small populations. Fortunately, there are cases in which
statistical methods that have been proposed in the litera-
ture for small populations were employed. To give but
two examples, a series of n-of-1 trials were conducted to
evaluate therapies in patients with hereditary angioedema
[18], propensity scores were used to match patients with
Gaucher disease type I who received different doses of en-
zyme therapy [17]. Propensity scores allow for a design
and an analysis of an observational study that mimic some
of the particular characteristics of an RCT [46]. Condi-
tional on the propensity score, the distribution of observed
baseline covariates will be similar between treated and un-
treated subjects.
Secondly, the imposed restriction of considering only
studies with at least 20 participants receiving the inter-
vention of interest implies that some evidence for evalu-
ating therapies in paediatric MS and CJD is excluded
from this review. On the basis of an initial screening of
the titles and abstracts found via the databases PubMed
and CENTRAL for paediatric MS (CJD), 18 (13) records
out of a total of 130 (124) records, most of which are
single case reports, are excluded because they did not
meet our imposed restriction.
Finally, we only assessed the risk of bias for RCTs. For
controlled studies the domains in the standard tool of the
Cochrane Collaboration could also usefully be assessed
when the allocation is not randomized [23]. As suggested
in [23], for non-randomized studies an additional domain
to assess the risk of bias due to confounding should be
added. However, since some of selected studies are uncon-
trolled before-after trials, we decided not to classify the
observational studies according to this risk of bias tool.
Assessing the extent of the risk of bias of the observational
studies that are considered in this review is a topic that is
left for further research.
Conclusions
In light of the lack of any class I level evidence on the ef-
fects of therapeutic interventions that is available in the
paediatric MS population, it would be desirable to have
Table 2 Risk of bias assessment of the RCTs on CJD [38, 39, 41] and on paediatric MS [28] (+ low risk of bias, ? unclear risk
of bias, - high risk of bias)
Reference Random sequence
generation
(selection bias)
Allocation
concealment
(selection bias)
Blinding of participants
and personnel
(performance bias)
Blinding of
outcome assessment
(detection bias)
Incomplete outcome
data (attrition bias)
Selective reporting
(reporting bias)
[41] + + + + + +
[39] + + + + + +
[38] + + + + + +
[28] + ? - ? + +
Table 3 Quality assessment of the studies on paediatric MS
(References [28–32, 34–37, 60–62]) and on CJD (References
[38–41, 43, 44, 63])
Studies on paediatric MS
AAN scale Oxford quality scale for RCTs References
Class II 2 points [28]
Class III n/a [29, 30, 37, 60, 62]
Class IV n/a [31, 32, 34–36, 61]
Studies on CJD
AAN scale Oxford quality scale for RCTs References
Class I 5 points [39, 41]
Class I 4 points [38]
Class III n/a [40, 43, 44, 63]
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class I level results for this subgroup of patients. This is
because an RCT in paediatric patients with MS is essen-
tial to reduce the use of medications that are currently
off-label and to ensure that children and adolescents are
exposed to safe as well as effective treatments. However,
trials in the paediatric MS population are confronted
with the general practical problem of only a small num-
ber of patients available for inclusion. On the one hand,
the sample size should be kept as small as possible in
order to include no more patients in a trial than neces-
sary with the objective of minimizing unnecessary risks.
On the other hand, the sample size should be large
enough to ensure statistical power. One way to reduce
the trial sample size is to use adaptive designs, of
which two types are response-adaptive randomization
and sequential trials [47]. Whereas in response-adaptive
randomization a greater proportion of patients is assigned
to the seemingly more effective treatment while reducing
overall trial enrollment, in sequential trials data are ana-
lyzed intermittently to guide decisions on termination
when safety concerns, futility, efficacy, or a combination
of these factors is demonstrated. To achieve the same
power for a given treatment effect, studies with an interim
analysis have a larger maximum sample size than the
fixed sample size design, but the expected sample
size, accounting for the gain achieved by early stop-
ping, will typically be smaller for sequential designs
than for fixed sample size designs.
Furthermore, ethical challenges of paediatric studies
do exist [48]. For example, a placebo-controlled design
requires that some participants forego active or possibly
effective therapy, which could be a more serious issue in
children compared to adults. As a remedy, one might
consider alternative designs instead such as add-on stud-
ies, active comparator arm studies, dose-ranging studies
or deferred-treatment arm studies. A phase III, double-
blind, randomised, active-controlled trial to evaluate
safety and efficacy of fingolimod versus interferon beta-
1a is currently recruiting paediatric patients with MS
(ClinicalTrials.gov identifier: NCT01892722). In this
RCT, double-dummy masking is required for blinding.
Placebo intramuscular injections are obtained by allo-
cating syringes matched in appearance to the active
interferon beta-1a intramuscular syringes.
For approval of fingolimod and other pharmacological
agents for children and adolescents with MS, paediatric
investigation plans are required by the EMA (see for ex-
ample [49]). These plans are aimed at ensuring the ne-
cessary data are obtained through studies in children
and adolescents to support the medicine’s authorisation
for use in this subgroup of patients. In any case, estab-
lishing collaborative (e.g., multicentre and multinational)
trials should be a priority in rare conditions in general
and in rare paediatric populations in particular.
While in general we would call for higher level evi-
dence, there might be settings in which observational
studies only could be justified considering the ethical
and logistical difficulties in conducting an RCT. In [18],
a few examples are presented for which an experimental
treatment exists that is markedly better than the stand-
ard treatment. In such settings it may be more efficient
to run a single-arm trial with all patients receiving the
new treatment instead of an RCT. However, sufficient
knowledge about the clinical course of the disease is re-
quired as this type of marked efficacy would typically
be seen only in situations in which an understanding of
the disease process has led to a therapy targeted to that
process [18].
In situations where randomization is difficult to achieve,
methods that incorporate data from other sources in the
estimation of the treatment effects may be beneficial. In-
formation external to the study that can be used on the
experimental and control arms could stem, for example,
from elicitation of experts [50, 51] or related patient popu-
lations [52]. Especially in the pediatric MS context a possi-
bility is the extrapolation from adults [53, 54]. If the
assumption can be justified that the disease is similar in
children and adults and e.g., pre-dominantly older chil-
dren after puberty are affected that may not be so different
to adults, then there may be no need to generate inde-
pendent level I evidence in children.
Examples where less than the required number of pa-
tients are available for randomization include an unbal-
anced RCT in patients with ankylosing spondylitis [55], an
ongoing paediatric study in Alport syndrome [56] and an
RCT in patients with early CJD [57]. These three examples
may call for the use of methods of generalised evidence
synthesis [15, 58], in which studies from different designs
are pooled in order to estimate quantities of interest. Vari-
ous methods for pooling are available [15, 58]. They all
share the aim not to eliminate observational studies totally,
but rather to provide the information needed to compen-
sate for specific weaknesses of such studies. Generalized
evidence synthesis then essentially comes down to making
decisions on how and to what extent to discount the
observational data. In [55], patients were randomly
assigned (in a 4:1 ratio) to either treatment or placebo. For
the evaluation of the placebo effect, data from eight
previous trials in patients with ankylosing spondylitis
were included. The information contained in these
trials was transformed into an informative prior dis-
tribution by means of the methodology described in
[59]. The ongoing trial in paediatric Alport patients
aims to combine the treatment effect estimates from
the randomized comparison with Alport registry data
[56]. A meta-analysis combining evidence on the ef-
fects of doxycycline in patients with early CJD from
both a randomized study and a non-randomized study
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is the subject of current research of members of the
team of co-authors of this review [57].
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